

[Tiotropium bromide](#)

Essential medicine status

Section:

[25. Medicines acting on the respiratory tract 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease](#)

ATC codes: [R03BB04](#)

Indication

Chronic obstructive pulmonary disease ICD11 code: [CA22](#)

INN

Tiotropium bromide

Medicine type

Chemical agent

List type

Core

Formulations

Respiratory > Inhalation > powder: 18 µg in capsule

Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler ; 2.5 µg per actuation in soft mist inhaler

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

[aclidinium](#) (ATC codes: [R03BB05](#))

[glycopyrronium](#) (ATC codes: [R03BB06](#))

[umeclidinium](#) (ATC codes: [R03BB07](#))

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Read more [about patents](#).

Wikipedia

[Tiotropium bromide](#)

DrugBank

[Tiotropium bromide \(Tiotropium\)](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes to the listing of tiotropium on the EML: - update the listing description of inhalation delivery systems for consistency across the Model Lists and to better reflect product characteristics.